Johnson & Johnson gene therapy update – What happens now?
The latest research news from Retina UK.
Search
Search results
Potential drug targets identified for RP
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.
Thomas Pocklington Trust and Sight Loss Councils ‘Cut it back’ campaign
TPT and Sight Loss Councils: Cut it back campaign
Involving our community
Our community is informed and knowledgeable about current research projects into the cause(s) of and treatments for these conditions.
Opus Genetics – the next BEST thing!
The latest research news from Retina UK.
Research grants
Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Meet our volunteers: Martin Hills
Martin started volunteering for Retina UK in 2014 after retiring as a Chartered Civil Engineer.
Look Forward – Spring 2023 – Issue 179
The Spring 2023 edition of the Retina UK newsletter, Look Forward, which includes articles about our upcoming events, research updates and more.
Types of genetic testing
This page explains the different types of genetic tests: diagnostic testing, predictive testing, carrier testing and research testing